{
    "title": "CAP vs Cancer",
    "inventor_name": "Jerome Canady",
    "publication_year": 2019,
    "device_name": "Canady Cold Plasma Conversion System",
    "goal": "Selectively ablate residual cancerous tissue during or without damaging surrounding healthy tissue.",
    "problem_addressed": "Microscopic tumor remnants left after surgery cause cancer recurrence; current modalities cannot reliably remove these cells.",
    "concept_summary": "A pen-like electrosurgical scalpel converts a high-frequency generator to emit a cold atmospheric plasma (CAP) jet. The plasma generates reactive oxygen species (ROS) that selectively kill cancer cells while sparing normal tissue. The system is FDA-approved for a Phase I clinical trial.",
    "detailed_description": "The device integrates a high-frequency electrosurgical generator with a cold plasma jet nozzle. Helium (or helium-oxygen mixtures) are ionized at atmospheric pressure to produce a near-room-temperature plasma containing radicals (OH*), superoxide (O_2^-), hydrogen peroxide (H_2O_2), nitrite (NO_2^-) and UV photons. The jet is applied to the surgical site for 2-7 minutes, delivering ROS that induce oxidative damage and apoptosis in cancer cells. Pre-clinical work demonstrated selective cytotoxicity in vitro (breast, glioblastoma, metastatic bone cancer lines) and in vivo (mouse glioblastoma models). Compassionate-use cases and a planned multi-center Phase I trial (~=20 patients) have been FDA-cleared.",
    "category": "Medical & Dental Technologies",
    "principles": [
        "Cold atmospheric plasma generation",
        "Reactive oxygen species mediated cytotoxicity",
        "High-frequency electrosurgical conversion",
        "Selective plasma-induced ablation"
    ],
    "scientific_domains": [
        "Plasma Physics",
        "Oncology",
        "Biomedical Engineering"
    ],
    "mechanisms_of_action": [
        "Generation of short- and long-lived ROS",
        "Oxidative damage to cancer cell membranes and DNA",
        "Induction of apoptosis in tumor cells",
        "Preservation of normal tissue due to limited penetration depth"
    ],
    "materials": [
        "Helium",
        "Oxygen",
        "Water vapor",
        "Hydrogen peroxide (as a ROS product)",
        "Nitrite ions"
    ],
    "energy_sources": [
        "High-frequency electrical power"
    ],
    "inputs": [
        "Electrical power",
        "Helium/He-O_2 gas flow",
        "Target tissue (cancerous cells)"
    ],
    "outputs": [
        "Cold plasma jet",
        "Reactive oxygen species (OH*, O_2^-, H_2O_2, NO_2^-)",
        "UV photons"
    ],
    "claimed_performance": "Selective killing of cancer cells up to 80 % reduction in viability in vitro; effective tumor ablation in mouse glioblastoma models; FDA-cleared Phase I trial for residual tumor removal.",
    "experimental_evidence": "In-vitro cell death assays on breast, glioblastoma, and metastatic bone cancer lines; animal studies showing tumor growth suppression; compassionate-use clinical cases; FDA Phase I trial approval.",
    "replication_status": "Multiple independent studies published (2013-2018) and a planned multi-center Phase I clinical trial; no commercial scale-up reported.",
    "keywords": [
        "Cold atmospheric plasma",
        "CAP",
        "Reactive oxygen species",
        "Selective ablation",
        "Cancer surgery",
        "Electrosurgical scalpel",
        "Phase I clinical trial"
    ],
    "related_technologies": [
        "Electrosurgical scalpel",
        "Plasma medicine devices",
        "Laser ablation"
    ],
    "controversy_level": "low",
    "confidence_score": 0.9,
    "practicability_score": 0.8,
    "fringe_score": 0.2,
    "evidence_strength": 0.8,
    "risk_score": 0.2,
    "trl_estimate": 6,
    "source_urls": [
        "https://www.purdue.edu/newsroom/releases/2019/Q3/treat-cancer-with-cold-plasma-purdue-aerospace-engineer-helps-bring-first-clinical-trial.html",
        "https://jhu.pure.elsevier.com/en/publications/the-effect-of-cold-atmospheric-plasma-treatment-on-cancer-stem-ce-3",
        "https://arxiv.org/pdf/1804.08421",
        "https://www.nature.com/articles/srep18339",
        "https://www.mdpi.com/2072-6694/9/6/61",
        "https://www.researchgate.net/publication/256614357_Cold_Atmospheric_Plasma_for_Selectively_Ablating_Metastatic_Breast_Cancer_Cells",
        "https://www.mdpi.com/2571-6182/1/1/19",
        "https://www.nature.com/articles/s41598-018-33914-w"
    ],
    "organizations": [
        "U.S. Medical Innovations LLC",
        "Jerome Canady Research Institute for Advanced Biological and Technological Sciences",
        "Purdue University",
        "The George Washington University"
    ],
    "applications": [
        "Intra-operative tumor margin ablation",
        "Adjunct to conventional cancer surgery",
        "Potential outpatient treatment for superficial tumors"
    ],
    "limitations": [
        "Limited penetration depth of cold plasma (effective only on surface or near-surface tissue)",
        "Requires specialized high-frequency generator and gas supply",
        "Clinical efficacy still under investigation (Phase I only)",
        "Potential variability in ROS production depending on nozzle geometry and gas flow"
    ],
    "open_questions": [
        "Long-term safety and possible side effects of repeated plasma exposure",
        "Optimal treatment parameters (duration, power, gas composition) for different tumor types",
        "Scalability to larger surgical fields and deeper tumors",
        "Mechanistic differences between direct plasma and CAP-stimulated media"
    ],
    "red_flags": [],
    "evidence_quotes": [
        "Cold atmospheric plasma selectively kills cancer cells in animal models (British Journal of Cancer, 2011).",
        "The device targets only tumors, leaving surrounding tissue unharmed, as demonstrated in vitro, in vivo and in FDA-approved compassionate use cases.",
        "The AuCAP device can be safely used in mice, resulting in suppression of glioblastoma tumor growth.",
        "CAP treatment reduced viability of triple-negative breast cancer cells up to 80 % without thermal damage.",
        "FDA cleared the technology for a Phase I clinical trial in 20 patients."
    ]
}